Viret J F, Favre D
Swiss Serum and Vaccine Institute, Berne.
Biologicals. 1994 Dec;22(4):361-72. doi: 10.1006/biol.1994.1055.
A considerable interest exists worldwide in the development of live attenuated oral vaccines against diarrhoeal diseases. In addition to vaccination against the corresponding pathogens, such vaccine strains can be used as carriers for the expression of protective antigens from other organisms. The antigenic repertoire of a given vaccine strain may thereby be extended, potentially leading to a bivalent vaccine. The lipopolysaccharide is known to be a major antigenic surface component of bacterial enteric pathogens. The feasibility of the development of combined vaccines based on live attenuated carriers expressing two O-serotype specificities is illustrated here by the development of candidate live oral vaccines against Shigella sonnei using Salmonella typhi and Vibrio cholerae as carriers. Various factors that may limit the potential of such hybrid strains as bivalent vaccines are discussed.
全球对于开发针对腹泻疾病的减毒活口服疫苗有着浓厚兴趣。除了针对相应病原体进行疫苗接种外，此类疫苗菌株还可作为载体用于表达来自其他生物体的保护性抗原。由此，给定疫苗菌株的抗原库可能得以扩展，进而有可能产生二价疫苗。已知脂多糖是细菌性肠道病原体的主要抗原表面成分。本文通过利用伤寒沙门氏菌和霍乱弧菌作为载体开发针对宋内志贺氏菌的候选口服活疫苗，阐述了基于表达两种O血清型特异性的减毒活载体开发联合疫苗的可行性。文中还讨论了可能限制此类杂交菌株作为二价疫苗潜力的各种因素。
